With the recent FDA-approval of Bayer’s Eylea HD 8mg as a durable long-term treatment for Wet AMD and the approval of Genentech’s Vabysmo to be used as therapeutic treatment for RVO, 2024 was predicted to be a big year for the retinal vascular disease drug development as the demand is increasing for therapies to slow down or halt the progression of retinal neovascularization, providing a shining opportunity for drug developers!

Designed alongside experts from retinal preclinical and clinical R&D from the likes of Novartis, Bayer, Boehringer Ingelheim, Ocular Therapeutics and Roche, this industry-focussed agenda tackled the preclinical and translational challenges when fast-tracking drugs into the clinic as well as discovery of novel targets and new modalities to accommodate for the large untreated patient population suffering from retinal neovascularization and blindness.

What's Was New for 2024?


Fresh perspectives from new companies that spoke at the 2024 meeting including Aviceda Therapeutics, Bayer, Boehringer Ingelheim, OcuTerra, Novartis, Genentech, and Adverum Biotechnologies


16+ brand-new speakers out of the 18+ speaker faculty consisting of industry experts and academic leaders working on preclinical models, choroidal neovascularization, retinal inflammation, durable drug delivery to the retinal vascular system and more


Robust new content that focused on industry-specific topics such as new targets, in vivo and in vitro models, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization

Who Attended?

Attendee Breakdown

Hear What Our 2023 Attendees Had to Say:

“The conference was very engaging. Lots of new ways of networking adapted in this conference such as speed networking, standing table to have lunch and panel discussions where I got to meet and network with many people” 

Senior Scientist, Oxular 


“Quality lectures and the rotating network opportunities were excellent” 

Scientific Advisory Board, Glycadia Inc.